Evidence map›Paper›PMID 18272845›Full record

ArticleJournal of the American Society of Nephrology : JASN2008

Caspase-3 gene deletion prolongs survival in polycystic kidney disease.

Yunxia Tao, Iram Zafar, Jun Kim, Robert W Schrier, Charles L Edelstein

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling.International journal of molecular sciences · 2021
    Review
  5. Review
  6. Article
  7. Review
  8. A study of sirolimus and mTOR kinase inhibitor in a hypomorphicAmerican journal of physiology. Renal physiology · 2019
    Article
  9. MicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease.Journal of the American Society of Nephrology : JASN · 2016
    Article
  10. Article
  11. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015
    Article
  12. Article
  13. Polycystins and cellular Ca2+ signaling.Cellular and molecular life sciences : CMLS · 2013
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.American journal of physiology. Renal physiology · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yunxia TaoDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, Box C281, 4200 E. 9th Avenue, Denver, CO 80262, USA.
Iram Zafar
Jun Kim
Robert W Schrier
Charles L Edelstein

Funding

Regulation of Growth and Epithelial Transport in ADPKDP01DK034039 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI SCHRIER, ROBERT W · 1986 to 2005
$6.3M
Mammalian target of rapamycin (mTOR) signaling in polycystic kidney disease (PKD)R01DK074835 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI EDELSTEIN, CHARLES LOUIS · 2007 to 2011
$1.8M
THE ROLE OF VEGF ON PDPKD DISEASE PROGRESSIONK01DK067191 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI TAO, YUNXIA · 2005 to 2010
$651k
NIDDK NIH HHS K01 DK067191NIDDK NIH HHS K08-DK067191NIDDK NIH HHS P01 DK034039NIDDK NIH HHS P01-DK-34039NIDDK NIH HHS R01 DK074835NIDDK NIH HHS R01-DK074835
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene DeletionAnimalsCaspase 3MicePolycystic Kidney DiseasesSurvival RateCaspase 3

Identifiers

PMID18272845
PMCPMC2390972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.